(NASDAQ: IOVA) Iovance Biotherapeutics's forecast annual revenue growth rate of 32.18% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.02%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Iovance Biotherapeutics's revenue in 2026 is $324,969,000.On average, 12 Wall Street analysts forecast IOVA's revenue for 2026 to be $167,205,344,694, with the lowest IOVA revenue forecast at $156,257,025,183, and the highest IOVA revenue forecast at $175,884,277,331. On average, 11 Wall Street analysts forecast IOVA's revenue for 2027 to be $233,031,153,192, with the lowest IOVA revenue forecast at $199,760,401,512, and the highest IOVA revenue forecast at $269,676,542,041.
In 2028, IOVA is forecast to generate $350,128,798,079 in revenue, with the lowest revenue forecast at $248,590,721,882 and the highest revenue forecast at $527,258,746,848.